We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PharmaFluidics NV Announced an Extra 2.7 Million Euros of Additional Funding
Product News

PharmaFluidics NV Announced an Extra 2.7 Million Euros of Additional Funding

PharmaFluidics NV Announced an Extra 2.7 Million Euros of Additional Funding
Product News

PharmaFluidics NV Announced an Extra 2.7 Million Euros of Additional Funding


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PharmaFluidics NV Announced an Extra 2.7 Million Euros of Additional Funding"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PharmaFluidics NV announced today that it has raised 2.7 million euro of additional funding. The funding was subscribed by a consortium of PharmaFluidics’ existing shareholders, new investors and management. Shareholders include Qbic Arkiv Fund, the Flemish investment company PMV, Theodorus Fund, Innovation Fund and Volksvermogen.

The funds will be used to expand the company’s team and efforts to commercialize its proprietary µPAC™ micro-chip based chromatography cartridges for use in biomarker, diagnostics and drug R&D applications worldwide.

Johan Devenyns, Managing Director PharmaFluidics: “Today, our µPAC™ cartridges already convincingly outperform state-of-the-art nano-LC columns currently used, as demonstrated by a variety of real-life proteomics, metabolomics and lipidomics lab analysis tests. Our micro-chip based chromatography cartridges provide substantial added value and time savings potential for biomarker and bio-similar developers. The renewed commitment of shareholders confirms their trust in the technology and potential of the company and team, associates and advisors”.

The key expertise and IP portfolio include the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of Centers of Excellence and pioneer users to develop an increasing range of applications.

This article has been republished from materials provided by PharmaFluidics. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement